FDA approved drugs:
| # |
|
Drug Name |
Active Ingredient(s) 18
|
Company |
Approval Date |
| 1 |
|
Cervarix
18
49
|
Human Papillomavirus Bivalent (Types 16 and 18) Vaccine, Recombinant |
GlaxoSmithKline |
October 2009 |
Disease/s that Drug Treats:prevention of cervical cancer and cervical intraepithelial neoplasia caused by HPV types 16 and 18
Indications and Usage:
18
DrugBank Targets:
-
Mechanism of Action:
18
Target: IgG neutralizing antibodies directed against HPV-L1 capsid proteins
Action: activates/ provokes production
FDA: -
|
| 2 |
|
Gardasil
18
49
|
quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine |
Merck |
June 2006 |
Disease/s that Drug Treats:Cervical Cancer Caused by Human Papillomavirus
Indications and Usage:
18
GARDASIL is a vaccine indicated in girls and women 9 through 26years of age for the prevention of the following diseases caused byHuman Papillomavirus (HPV) types included in the vaccine: Cervical, vulvar, vaginal, and anal cancer caused by HPV types 16and 18 (1.1) Genital warts (condyloma acuminata) caused by HPV types 6 and11 (1.1)And the following precancerous or dysplastic lesions caused by HPVtypes 6, 11, 16, and 18: Cervical intraepithelial neoplasia (CIN) grade 2/3 and Cervicaladenocarcinoma in situ (AIS) (1.1) Cervical intraepithelial neoplasia (CIN) grade 1 (1.1) Vulvar intraepithelial neoplasia (VIN) grade 2 and grade 3 (1.1) Vaginal intraepithelial neoplasia (VaIN) grade 2 and grade 3 (1.1) Anal intraepithelial neoplasia (AIN) grades 1, 2, and 3 (1.1)GARDASIL is indicated in boys and men 9 through 26 years of age forthe prevention of the following diseases caused by HPV types includedin the vaccine: Anal cancer caused by HPV types 16 and 18 (1.2) Genital warts (condyloma acuminata) caused by HPV types 6 and11 (1.2)And the following precancerous or dysplastic lesions caused by HPVtypes 6, 11, 16, and 18: Anal intraepithelial neoplasia (AIN) grades 1, 2, and 3. (1.2)Limitations of GARDASIL Use and Effectiveness: GARDASIL does not eliminate the necessity for women tocontinue to undergo recommended cervical cancer screening.(1.3, 17) Recipients of GARDASIL should not discontinue anal cancerscreening if it has been recommended by a health care provider.(1.3, 17) GARDASIL has not been demonstrated to provide protectionagainst disease from vaccine and non-vaccine HPV types to whicha person has previously been exposed through sexual activity.(1.3, 14.4, 14.5) GARDASIL is not intended to be used for treatment of activeexternal genital lesions; cervical, vulvar, vaginal, and analcancers; CIN; VIN; VaIN, or AIN. (1.3) GARDASIL has not been demonstrated to protect againstdiseases due to HPV types not contained in the vaccine. (1.3,14.4, 14.5) Not all vulvar, vaginal, and anal cancers are caused by HPV, andGARDASIL protects only against those vulvar, vaginal, and analcancers caused by HPV 16 and 18. (1.3) GARDASIL does not protect against genital diseases not causedby HPV. (1.3) Vaccination with GARDASIL may not result in protection in allvaccine recipients. (1.3) GARDASIL has not been demonstrated to prevent HPV-relatedCIN 2/3 or worse in women older than 26 years of age. (14.7)
DrugBank Targets:
-
Mechanism of Action:
18
Target: humoral immune response
Action: inducer
FDA: HPV only infects human beings. Animal studies with analogous animal papillomaviruses suggest thatthe efficacy of L1 VLP vaccines may involve the development of humoral immune responses. Humanbeings develop a humoral immune response to the vaccine, although the exact mechanism of protectionis unknown.
|
| 3 |
|
Tafinlar
18
49
|
DABRAFENIB MESYLATE |
GlaxoSmithKline |
May 2013 |
Disease/s that Drug Treats:unresectable or metastatic melanoma with BRAF V600E mutation
Indications and Usage:
18
TAFINLAR is a kinase inhibitor indicated as a single agent for thetreatment of patients with unresectable or metastatic melanoma withBRAF V600E mutation as detected by an FDA-approved test. (1.1, 2.1) TAFINLAR in combination with trametinib is indicated for the treatmentof patients with unresectable or metastatic melanoma with BRAF V600Eor V600K mutations as detected by an FDA-approved test. The use incombination is based on the demonstration of durable response rate.Improvement in disease-related symptoms or overall survival has notbeen demonstrated for TAFINLAR in combination with trametinib. (1.2,2.1, 14.2)Limitation of Use: TAFINLAR is not indicated for treatment of patients withwild-type BRAF melanoma. (1.3, 5.2)
DrugBank Targets:
16
1. Serine/threonine-protein kinase B-raf;2. RAF proto-oncogene serine/threonine-protein kinase;3. Serine/threonine-protein kinase SIK1;4. Serine/threonine-protein kinase Nek11;5. LIM domain kinase 1
Mechanism of Action:
18
Target: some mutated forms of BRAF kinases, wild-type BRAF and CRAF kinases
Action: inhibitor
FDA: Dabrafenib is an inhibitor of some mutated forms of BRAF kinases with in vitro IC50 values of0.65, 0.5, and 1.84 nM for BRAF V600E, BRAF V600K, and BRAF V600D enzymes,respectively. Dabrafenib also inhibits wild-type BRAF and CRAF kinases with IC50 values of 3.2and 5.0 nM, respectively, and other kinases such as SIK1, NEK11, and LIMK1 at higherconcentrations. Some mutations in the BRAF gene, including those that result in BRAF V600E,can result in constitutively activated BRAF kinases that may stimulate tumor cell growth [seeIndications and Usage (1)]. Dabrafenib inhibits BRAF V600 mutation-positive melanoma cellgrowth in vitro and in vivo.Dabrafenib and trametinib target two different tyrosine kinases in the RAS/RAF/MEK/ERKpathway. Use of dabrafenib and trametinib in combination resulted in greater growth inhibitionof BRAF V600 mutation-positive melanoma cell lines in vitro and prolonged inhibition of tumorgrowth in BRAF V600 mutation positive melanoma xenografts compared with either drug alone.
|
| 4 |
|
Zelboraf
18
49
|
VEMURAFENIB |
Roche |
August of 2011 |
Disease/s that Drug Treats:BRAF + melanoma
Indications and Usage:
18
ZELBORAF® is a kinase inhibitor indicated for the treatment of patients withunresectable or metastatic melanoma with BRAF V600E mutation as detectedby an FDA-approved test. (1, 2.1)Limitation of Use: ZELBORAF is not indicated for treatment of patients withwild-type BRAF melanoma. (2.1, 5.2)
DrugBank Targets:
16
1. Serine/threonine-protein kinase B-raf
Mechanism of Action:
18
Target: some mutated forms of BRAF serinethreoninekinase
Action: inhibitor
FDA: Vemurafenib is a low molecular weight, orally available inhibitor of some mutated forms of BRAF serinethreoninekinase, including BRAF V600E. Vemurafenib also inhibits other kinases in vitro such as CRAF,ARAF, wild-type BRAF, SRMS, ACK1, MAP4K5, and FGR at similar concentrations. Some mutations in theBRAF gene including V600E result in constitutively activated BRAF proteins, which can cause cellproliferation in the absence of growth factors that would normally be required for proliferation. Vemurafenibhas anti-tumor effects in cellular and animal models of melanomas with mutated BRAF V600E.
|
Drugs for Papilloma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 262)
| # |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
| 1 |
|
Cidofovir |
Approved |
Phase 4,Phase 2,Phase 1 |
|
113852-37-2 |
60613
|
|
Synonyms:
({[(2S)-1-(4-amino-2-oxopyrimidin-1(2H)-yl)-3-hydroxypropan-2-yl]oxy}methyl)phosphonic acid
({[(S)-1-(4-amino-2-oxo-1,2-dihydropyrimidin-1-yl)-3-hydroxypropan-2-yl]oxy}methyl)phosphonic acid
(2S)-3-Hydroxy-2-phosphonylmethoxypropyl-cytosine
(S)-(3-(4-amino-2-Oxopyrimidin-1(2H)-yl)-1-hydroxypropan-2-yloxy)methylphosphonate
(S)-(3-(4-amino-2-Oxopyrimidin-1(2H)-yl)-1-hydroxypropan-2-yloxy)methylphosphonic acid
(s)-[[2-(4-amino-2-oxo-1(2h)-pyrimidinyl)-1-(hydroxymethyl)ethoxy]methyl]phosphonic acid
(S)-1-(3-Hydroxy-2-phosphonomethoxypropyl)cytosine
(S)-1-[3-Hydroxy-2-(phosphonomethoxy)propyl]cytosine
(S)-1-[3-hydroxy-2-(phosphonylmethoxy)-propyl]cytosine
(S)-1-[3-Hydroxy-2-(phosphonylmethoxy)propyl]cytosine
(S)-2-(4-Amino-2-oxo-1(2H)-pyrimidinyl-1-(hydroxymethyl)ethoxy)methyl phosphonic acid
(S)-HPMPC
[(2S)-1-(4-amino-2-oxopyrimidin-1-yl)-3-hydroxypropan-2-yl]oxymethylphosphonic acid
[(S)-2-(4-amino-2-oxo-2H-Pyrimidin-1-yl)-1-hydroxymethyl-ethoxymethyl]-phosphonate
[(S)-2-(4-amino-2-oxo-2H-Pyrimidin-1-yl)-1-hydroxymethyl-ethoxymethyl]-phosphonic acid
[(S)-2-(4-Amino-2-oxo-2H-pyrimidin-1-yl)-1-hydroxymethyl-ethoxymethyl]-phosphonic acid
[[(S)-2-(4-amino-2-oxo-1(2H)-pyrimidinyl)-1-(hydroxymethyl)ethoxy]methyl]phosphonic acid
1-((3-Hydroxy-2-phosphonylmethoxy)propyl)cytosine
1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine
1-(3-Hydroxy-2-phosphonylmethoxypropyl)cytosine
1-(S)-[3-Hydroxy-2-(phosphonomethoxy)propyl]cytosine
1-[(S)-3-Hydroxy-2-(phosphonomethoxy)propyl]cytosine
1-[(S)-3-Hydroxy-2-(phosphonomethoxy)propyl]-cytosine dihydrate
113852-37-2
120362-37-0 (hydrochloride salt)
149394-66-1
AC-1666
AC1L1TLB
AC1Q6C68
AKOS005145721
|
C8H14N3O6P
CDV
CHEBI:3696
CHEMBL152
CID60613
Cidofovir
Cidofovir (anhydrous)
Cidofovir (Vistide)
Cidofovir anhydrous
Cidofovir sodium
Cidofovir, (+-)-isomer
Cidofovir, (R)-isomer
Cidofovir, sodium salt
Cidofovirum
DB00369
Forvade
GS 0504
GS 504
GS-0504
GS504
GS-504
HPMPC
HSDB 7115
LS-106432
MolPort-005-935-597
NSC742135
S1516_Selleck
UNII-768M1V522C
Vistide
Vistide, Cidofovir
|
|
| 2 |
|
Polihexanide |
Approved, Investigational |
Phase 4 |
|
28757-47-3 |
|
|
Synonyms:
Polyhexamethylene biguanide
|
|
|
| 3 |
|
Chlorhexidine |
Approved, Vet_approved |
Phase 4 |
|
55-56-1 |
2713
9552079
|
|
Synonyms:
1,1 inverted exclamation marka-Hexamethylenebis[5-(4-chlorophenyl)biguanide]
1,1'-Hexamethylene bis(5-(p-chlorophenyl)biguanide)
1,1'-Hexamethylene bis(5-(P-chlorophenyl)biguanide)
1,1'-Hexamethylenebis(5-(p-chlorophenyl)biguanide)
1,1'-Hexamethylenebis[5-(4-chlorophenyl)biguanide
1,6-Bis(5-(p-chlorophenyl)biguandino)hexane
1,6-Bis(p-chlorophenyldiguanido)hexane
1,6-Di(4'-chlorophenyldiguanido)hexane
1,6-Di(N-p-chlorophenyldiguanido)hexane
24798_FLUKA
282227_ALDRICH
348031_ALDRICH
4-12-00-01201 (Beilstein Handbook Reference)
55-56-1
AB00053427
AB1003159
AVAGARD
BPBio1_000272
BRN 2826432
BSPBio_000246
BSPBio_001977
C06902
C22H30Cl2N10
CAS-55-56-1
CCRIS 9230
CHEBI:3614
CHEMBL790
Chlorhexidin
Chlorhexidin [Czech]
chlorhexidine
Chlorhexidine
Chlorhexidine (INN)
Chlorhexidine [INN:BAN]
Chlorhexidine Base
Chlorhexidine gluconate
Chlorhexidinum
Chlorhexidinum [INN-Latin]
CID9552079
Cloresidina
Cloresidina [DCIT]
Clorhexidina
Clorhexidina [INN-Spanish]
D07668
DB00878
Decanoylacetaldehyde Sodium Sulfide
Dentisept [veterinary]
Dentisept [veterinary] (TN)
DivK1c_000761
EINECS 200-238-7
Fimeil
Hexadol
Hibiclens
Hibispray
Hibistat
HMS1568M08
HSDB 7196
I06-0621
I14-0050
IDI1_000761
|
KBio1_000761
KBio2_000717
KBio2_003285
KBio2_005853
KBio3_001197
KBioGR_000774
KBioSS_000717
Lisium (*Dihydrochloride*)
LS-43917
Merfen-incolore
Merfen-incolore (TN)
MK-412A
MLS001332387
MLS001332388
MLS002154209
MolPort-002-541-741
N,N'-Bis(4-chlorophenyl)-3,12-diimino-2,4,11,13-tetraazatetradeca- nediimidamide
N,N'-bis(4-chlorophenyl)-3,12-diimino-2,4,11,13-tetraazatetradecanediimidamide
N,N'-Bis(4-chlorophenyl)-3,12-diimino-2,4,11,13-tetraazatetradecanediimidamide
N,N''''-hexane-1,6-diylbis[N'-(4-chlorophenyl)(imidodicarbonimidic diamide)]
N',N'''''-hexane-1,6-diylbis[N-(4-chlorophenyl)(imidodicarbonimidic diamide)]
NCGC00016246-01
NCGC00091025-01
NCGC00091025-02
NINDS_000761
Nolvasan
Nolvasan (*Diacetate*)
Novalsan
NSC526936
Oro-Clense
Peridex
Periogard
Prestwick_53
Prestwick0_000143
Prestwick1_000143
Prestwick2_000143
Prestwick3_000143
QTL1_000020
Rotersept
Savloclens
Savlon babycare
Sebidin A
SMR000857146
Sodium Houttuyfonamide
Soretol
SPBio_000210
SPBio_002185
Spectrum_000237
Spectrum2_000135
Spectrum3_000339
Spectrum4_000277
Spectrum5_001322
Sterido
Sterilon
STK089248
STOCK1S-18831
Superspray
Tubulicid
UNII-R4KO0DY52L
|
|
| 4 |
|
Imiquimod |
Approved, Investigational |
Phase 4,Phase 2,Phase 3,Phase 1 |
|
99011-02-6 |
57469
|
|
Synonyms:
1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine
1-(2-Methylpropyl)-1H-imidazole[4,5-c]quinoline-4-amine
1-(2-methylpropyl)imidazo[4,5-c]quinolin-4-amine
1-isobutyl-1H-imidazo(4,5-c)quinolin-4-amine
1-Isobutyl-1H-imidazo(4,5-c)quinolin-4-amine
1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
1-Isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
3M Brand of Imiquimod
4-amino-1-Isobutyl-1H-imidazo(4,5-c)quinoline
4-Amino-1-isobutyl-1H-imidazo(4,5-c)quinoline
4-Amino-1-isobutyl-1H-imidazo[4,5-c]quinoline
99011-02-6
AC1L1N2I
AC1Q4YO9
AC-529
Aldara
Aldara (TN)
Aldara, Imiquimod
BB_SC-2107
Beselna
BIDD:GT0859
C056493
CHEBI:36704
CHEMBL1282
CID57469
D02500
DB00724
DZ-2636
FT-0080222
HMS2090M14
|
I06-0624
I06-2289
I0747
I5159_SIGMA
imiquimod
Imiquimod
IMIQUIMOD
Imiquimod (JAN/USAN/INN)
Imiquimod [USAN:INN]
Imiquimod acetate
Imiquimodum
LS-178395
MLS000083577
MolPort-002-507-845
MTD-39
NCGC00070736-02
NSC369100
R 837
R-837
S 26308
S1211_Selleck
S-26308
SMR000048307
STK583860
TL8006059
TMX-101
UNII-P1QW714R7M
Zartra
ZINC19632912
Zyclara
|
|
| 5 |
|
Bleomycin |
Approved, Investigational |
Phase 4 |
|
11056-06-7 |
5360373
|
|
Synonyms:
(betaR)-N(alpha)-{[6-amino-2-((1S)-3-amino-1-{[(2S)-2,3-diamino-3-oxopropyl]amino}-3-oxopropyl)-5-methylpyrimidin-4-yl]carbonyl}-beta-{2-O-[3-O-(aminocarbonyl)-alpha-D-mannopyranosyl]-alpha-L-gulopyranosyloxy}-N-[(1R,2S,3S)-5-({(1S,2R)-1-[({2-[4-({[3-(dimethylsulfonio)propyl]amino}carbonyl)-2,4'-bi-1,3-thiazol-2'-yl]ethyl}amino)carbonyl]-2-hydroxypropyl}amino)-3-hydroxy-4-methyl-5-oxopentan-2-yl]-L-histidinamide
11056-06-7
11116-31-7
1400-95-9
3-[[2-[2-[2-[[(2S,3R)-2-[[(2S,3S,4R)-4-[[(2S)-2-[[6-amino-2-[(1S)-3-amino-1-[[(2S)-2,3-diamino-3-oxopropyl]amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[(2R,3S,4S,5S,6S)-3-[(2R,3S,4S,5R,6R)-4-carbamoyloxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-(1H-imidazol-5-yl)propanoyl]amino]-3-hydroxy-2-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]ethyl]-1,3-thiazol-4-yl]-1,3-thiazole-4-carbonyl]amino]propyl-dimethylsulfanium
3-[[2-[2-[2-[[(2S,3R)-2-[[(2S,3S,4R)-4-[[(2S,3R)-2-[[6-amino-2-[(1S)-3-amino-1-[[(2S)-2,3-diamino-3-oxopropyl]amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[(2R,3S,4S,5S,6S)-3-[(2R,3S,4S,5R,6R)-4-carbamoyloxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-(1H-imidazol-5-yl)propanoyl]amino]-3-hydroxy-2-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]ethyl]-1,3-thiazol-4-yl]-1,3-thiazole-4-carbonyl]amino]propyl-dimethylsulfanium
3-[[2-[2-[2-[[(2S,3R)-2-[[(2S,3S,4R)-4-[[(2S,3R)-2-[[6-amino-2-[(1S)-3-amino-1-[[(2S)-2,3-diamino-3-oxopropyl]amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[3-[4-carbamoyloxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-(1H-imidazol-5-yl)propanoyl]amino]-3-hydroxy-2-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]ethyl]-1,3-thiazol-4-yl]-1,3-thiazole-4-carbonyl]amino]propyl-dimethylsulfanium
37208-04-1
37293-16-6
37353-43-8
9041-93-4
9041-93-4 (sulfate (salt))
AC1L9UFF
AC1NSEJD
AC1NUTOQ
Almirall brand OF bleomycin sulfate
Bellon brand OF bleomycin sulfate
Bellon, bléomycine
Blanoxan
Blenoxane
Bleo
bleo Cell
bleo-Cell
BLEOcell
Bleocin
Bleogin
Bleolem
Bleomicin
Bleomicina
Bleomicina [INN-Spanish]
bleomycin
Bleomycin a(2)
Bleomycin A(2)
bleomycin a2
Bleomycin a2
Bleomycin A2
Bleomycin A2 & Bleomycin B2.
Bleomycin b(2)
Bleomycin B(2)
Bleomycin b2
Bleomycin B2
Bleomycin sulfate
Bleomycin sulphate
|
Bleomycine
Bleomycine [INN-French]
Bléomycine bellon
Bleomycins
Bleomycinum
Bleomycinum [INN-Latin]
Bleomycinum mack
BLM
Bristol myers squibb brand OF bleomycin sulfate
Bristol-myers squibb brand OF bleomycin sulfate
Bull brand OF bleomycin sulfate
C06854
C55H85N17O21S3
C55H86N17O21S3
CCRIS 2754
Cell pharm brand OF bleomycin sulfate
CHEBI:3139
CHEMBL403664
CID456190
CID5360373
CID5460769
DB00290
EINECS 234-356-5
HSDB 3208
Lemery brand OF bleomycin sulfate
LMPK14000006
LS-44860
LS-524
Lundbeck brand OF bleomycin sulfate
Mack brand OF bleomycin sulfate
Mack, bleomycinum
N(1)-[3-(dimethylsulfonio)propyl]bleomycinamide
N1-(3-(Dimethylsulfonio)propyl)bleomycinamide
NDC 0015-3010
NSC 125066
Pingyangmyvin A2
STOCK1N-74760
Sulfate, bleomycin
UNII-13M89UEA7W
UNII-40S1VHN69B
Zhengguangmycin A2
Zhengguangmycin A2 [Chinese]
|
|
| 6 |
|
Immunologic Factors |
|
Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 |
|
|
|
| 7 |
|
Immunoglobulins |
|
Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable |
|
|
|
| 8 |
|
Antibodies |
|
Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable |
|
|
|
| 9 |
|
Vaccines |
|
Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 |
|
|
|
| 10 |
|
Liver Extracts |
|
Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 |
|
|
|
| 11 |
|
Antiviral Agents |
|
Phase 4,Phase 3,Phase 2,Phase 1 |
|
|
|
| 12 |
|
Anti-Infective Agents |
|
Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable |
|
|
|
| 13 |
|
Anti-Bacterial Agents |
|
Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable |
|
|
|
| 14 |
|
Chlorhexidine gluconate |
|
Phase 4 |
|
|
|
| 15 |
|
Dermatologic Agents |
|
Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable |
|
|
|
| 16 |
|
Biguanides |
|
Phase 4 |
|
|
|
| 17 |
|
Anti-Infective Agents, Local |
|
Phase 4 |
|
|
|
| 18 |
|
Disinfectants |
|
Phase 4 |
|
|
|
| 19 |
|
Hypoglycemic Agents |
|
Phase 4 |
|
|
|
| 20 |
|
Heptavalent Pneumococcal Conjugate Vaccine |
|
Phase 4 |
|
|
|
| 21 |
|
MF59 oil emulsion |
|
Phase 4 |
|
|
|
| 22 |
|
Antibiotics, Antitubercular |
|
Phase 4,Phase 3,Phase 2,Phase 1 |
|
|
|
| 23 |
|
Adjuvants, Immunologic |
|
Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable |
|
|
|
| 24 |
|
Interferon Inducers |
|
Phase 4,Phase 2,Phase 3,Phase 1 |
|
|
|
| 25 |
|
interferons |
|
Phase 4,Phase 2,Phase 3,Phase 1 |
|
|
|
| 26 |
|
Insulin, Globin Zinc |
|
Phase 4,Phase 3 |
|
|
|
| 27 |
|
insulin |
|
Phase 4,Phase 3 |
|
|
|
| 28 |
|
Azithromycin |
Approved |
Phase 3,Not Applicable |
|
83905-01-5 |
55185
447043
|
|
Synonyms:
(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-11-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-2-ethyl-3,4,10-trihydroxy-13-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,6,8,10,12,14-heptamethyl-1-oxa-6-azacyclopentadecan-15-one
(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)13-((2,6-Dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribo-hexopyranosyl)oxy)-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-((3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranosyl)oxy)-1-oxa-6-azacyclopentadecan-15-one
(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-13-((2,6-Dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribo-hexopyranosyl)oxy)-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-((3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranosyl)oxy)-1-oxa-6-azacyclopentadecan-15-one
(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)13-((2,6-Dideoxy-3-C-methyl-3-O-methyl-a-L-ribo-hexopyranosyl)oxy)-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-((3,4,6-trideoxy-3-(dimethylamino)-b-D-xylo-hexopyranosyl)oxy)-1-oxa-6-azacyclopentadecan-15-one
(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)13-((2,6-Dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy)-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-((3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl)oxy)-1-oxa-6-azacyclopentadecan-15-one
(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-15-oxo-11-{[3,4,6-trideoxy-3-(dimethylamino)-b-D-xylo-hexopyranosyl]oxy}-1-oxa-6-azacyclopentadecan-13-yl 2,6-dideoxy-3-C-methyl-3-O-methyl-a-L-ribo-hexopyranoside
(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-15-oxo-11-{[3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranosyl]oxy}-1-oxa-6-azacyclopentadecan-13-yl 2,6-dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribo-hexopyranoside
121470-24-4
1-Oxa-6-azacyclopentadecan-15-one, 13-((2,6-dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribo-hexopyranosyl)oxy)-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-((3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranosyl)oxy)-,(2R-(2R*,3S*
75199_FLUKA
83905-01-5
9-Deoxo-9a-aza-9a-methyl-9a-homoerythromycin A
AC-16014
AC1L9KEG
Aritromicina
Azadose
Azasite
Azenil
Azifast
Azigram
Azimakrol
Azithramycine
azithromycin
Azithromycin & Tumor Necrosis Factor
Azithromycin (AIDS Initiative)
Azithromycin (anhydrous)
Azithromycin dihydrate
Azithromycin monohydrate
Azithromycin Monohydrate
Azithromycin pfizer brand
Azithromycine
Azithromycinum
Azitrocin
Azitromax
Azitromicina
Azitromin
Azythromycin
Bayer brand OF azithromycin dihydrate
BIDD:GT0792
Bio-0676
BRN 5387583
BSPBio_002285
C38H72N2O12
CCRIS 1961
CHEBI:2955
CHEMBL529
CID447043
CP62,993
CP-62993
CPD000471864
DCH3
Dihydrate, azithromycin
DivK1c_000233
DRG-0104
Funk brand OF azithromycin dihydrate
Goxal
Hemomycin
HMS1922G12
|
HMS2094M11
HMS500L15
HSDB 7205
IDI1_000233
KBio1_000233
KBio2_000787
KBio2_003355
KBio2_005923
KBio3_001505
KBioGR_000731
KBioSS_000787
Lesvi brand OF azithromycin dihydrate
LS-1834
Mack brand OF azithromycin dihydrate
Misultina
MLS001055353
MLS001066331
MLS001201763
MLS001304005
MLS001332499
MLS001332500
MolPort-002-507-426
Monohydrate, azithromycin
NCGC00090753-01
NCGC00090753-02
NINDS_000233
NSC643732
Pfizer brand OF azithromycin
Pfizer brand OF azithromycin dihydrate
Pharmacia brand OF azithromycin dihydrate
SAM002589961
SMR000471864
SPBio_001544
Spectrum_000307
SPECTRUM1503679
Spectrum2_001582
Spectrum3_000653
Spectrum4_000186
Spectrum5_001867
Sumamed
Toraseptol
Tromix
Ultreon
UNII-JTE4MNN1MD
Vinzam
Vita brand OF azithromycin dihydrate
XZ-450
Zentavion
ZIT
Zithromac
Zithromax
Zithromax IV
Zithromycin
Zitromax
Zitromax Avium 600
Zmas
Zmax
Z-Pak
|
|
| 29 |
|
Cetuximab |
Approved |
Phase 3,Phase 1,Phase 2,Not Applicable |
|
205923-56-4 |
56842117
2333
|
|
Synonyms:
205923-56-4
Anti EGFR
cetuximab
Cetuximab
Cétuximab
Cetuximab (genetical recombination)
Cetuximab (genetical recombination) (JAN)
|
Cetuximab (USAN/INN)
Cetuximabum
D03455
Erbitux
Erbitux (TN)
IMC-C225
Immunoglobulin G 1 (human-mouse monoclonal C 225 gamma 1 - chain anti-human epidermal growt factor receptor), disulfide wit human-mouse monoclonal C 225 kappa - chain, dimer
|
|
| 30 |
|
Benzocaine |
Approved, Investigational |
Phase 3 |
|
94-09-7, 1994-09-7 |
2337
|
|
Synonyms:
(P-(Ethoxycarbonyl)phenylamine
06952_FLUKA
112909_ALDRICH
112909_SIAL
1333-08-0
23239-88-5
23239-88-5 (hydrochloride)
4 Aminobenzoic Acid Ethyl Ester
4-(Ethoxycarbonyl)aniline
4-(Ethoxycarbonyl)phenylamine
4-14-00-01129 (Beilstein Handbook Reference)
4-Aminobenzoate
4-Aminobenzoate ethyl ester
4-Aminobenzoic acid
4-aminobenzoic acid ethyl ester
4-amino-benzoic acid ethyl ester
4-Aminobenzoic acid ethyl ester
4-Aminobenzoic acid, ethyl ester
4-Carbethoxyaniline
71123-91-6
94-09-7
94-09-7 (Parent)
A0271
AB00051923
AC1L1DGC
AC1Q341A
AC1Q64JE
Acetate, benzocaine
Acetate, Benzocaine
AE-562/40377256
Aethoform
Aethylium paraminobenzoicum
AI3-02081
AKOS000119763
Amben ethyl ester
Americaine
Anaesthan-syngala
Anaesthesin
Anaesthesinum
Anaesthin
Anestezin
Anestezin [Russian]
Anesthesin
Anesthesine
Anesthone
AR-1H9065
Baby anbesol
Baby Anbesol
BB_SC-0019
Bensokain
Benzoak
Benzocaina
Benzocaina [INN-Spanish]
benzocaine
Benzocaine
Benzocaine (USP/INN)
Benzocaine [INN:BAN]
Benzocaine acetate
Benzocaine Acetate
Benzocaine formate
Benzocaine Formate
Benzocaine hydrobromide
Benzocaine Hydrobromide
Benzocaine hydrochloride
Benzocaine Hydrochloride
Benzocaine methanesulfonate
Benzocaine Methanesulfonate
Benzocainum
Benzocainum [INN-Latin]
Benzoic acid, 4-amino-, ethyl ester
Benzoic acid, 4-amino-, ethyl ester, hydrochloride
Benzoic acid, amino-, ethyl ester
Benzoic acid, p-amino-, ethyl ester
BPBio1_001017
BRD-K75466013-001-05-2
BRN 0638434
BSPBio_000923
BSPBio_001908
C07527
CAS-94-09-7
Caswell No. 430A
CHEBI:116735
CHEMBL278172
Chloraseptic
CID2337
D001566
D00552
DB01086
Dermoplast
Diet ayds
DivK1c_000932
E1501_SIGMA
EINECS 202-303-5
EPA Pesticide Chemical Code 097001
Ethoform
Ethoforme
Ethyl 4-aminobenzoate
Ethyl 4-aminobenzoate hydrochloride
Ethyl 4-aminobenzoic acid
Ethyl aminobenzoate
Ethyl Aminobenzoate
Ethyl aminobenzoate (JP15)
Ethyl aminobenzoate (VAN)
Ethyl aminobenzoic acid
|
Ethyl PABA
Ethyl P-aminobenzenecarboxylate
Ethyl p-aminobenzoate
Ethyl p-Aminobenzoate
Ethyl P-aminobenzoate
Ethyl P-aminobenzoic acid
Ethyl p-aminophenylcarboxylate
Ethyl p-Aminophenylcarboxylate
Ethyl P-aminophenylcarboxylate
Ethyl P-aminophenylcarboxylic acid
ethylaminobenzoate-4
Ethylester kyseliny p-aminobenzoove
Ethylester kyseliny P-aminobenzoove
Ethylester kyseliny p-aminobenzoove [Czech]
Ethylis aminobenzoas
ETHYL-P-AMINOBENZOATE
Formate, benzocaine
Formate, Benzocaine
h-4-abz-oet
HMS1570O05
HMS1920G09
HMS2091M11
HMS502O14
HSDB 7225
Hurricaine
Hydrobromide, benzocaine
Hydrobromide, Benzocaine
Hydrochloride, benzocaine
Hydrochloride, Benzocaine
I05-0204
Identhesin
IDI1_000932
KBio1_000932
KBio2_000474
KBio2_003042
KBio2_005610
KBio3_001408
KBioGR_000658
KBioSS_000474
Keloform
LS-35847
Methanesulfonate, benzocaine
Methanesulfonate, Benzocaine
MLS001331704
MLS002153970
MolPort-000-871-526
NCGC00016352-01
NCGC00094598-01
NCGC00094598-02
nchembio.182-comp4
NINDS_000932
Norcain
Norcaine
Norcainum
NSC 122792
NSC 41531
NSC41531
NSC4688
Oprea1_750694
Oprea1_827402
Orabase-b
Ora-jel
Orthesin
Otocain
Outgro
p-(Ethoxycarbonyl)aniline
P-(Ethoxycarbonyl)aniline
P-Aminobenzoate
P-Aminobenzoic acid
p-Aminobenzoic acid ethyl ester
P-Aminobenzoic acid ethyl ester
p-Aminobenzoic acid, ethyl ester
p-Aminobenzoic ethyl ester
Parathesin
Parathesin (TN)
Parathesine
p-Carbethoxyaniline
P-Carbethoxyaniline
p-Ethoxycarboxylic aniline
p-Ethoxycarboxylic Aniline
P-Ethoxycarboxylic aniline
Prestwick_991
Prestwick0_000712
Prestwick1_000712
Prestwick2_000712
Prestwick3_000712
Slim mint gum
SMR000059025
Solarcaine
Solu H
SPBio_000134
SPBio_002844
Spectrum_000074
SPECTRUM1500139
Spectrum2_000117
Spectrum3_000314
Spectrum4_000249
Spectrum5_000860
STK043620
Topcaine
UNII-U3RSY48JW5
WLN: ZR DVO2
ZINC12358719
|
|
| 31 |
|
tannic acid |
Approved |
Phase 3 |
|
|
|
| 32 |
|
Penicillin G |
Approved, Vet_approved |
Phase 3 |
|
61-33-6 |
5904
|
|
Synonyms:
(2S,5R,6R)-3,3-Dimethyl-7-oxo-6-(phenylacetamido)-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate
(2S,5R,6R)-3,3-dimethyl-7-oxo-6-(phenylacetamido)-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
(2S,5R,6R)-3,3-Dimethyl-7-oxo-6-(phenylacetamido)-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
(5R,6R)-Benzylpenicillin
(Phenylmethyl)penicillin
(Phenylmethyl)penicillinic acid
113-98-4 (mono-potassium salt)
2,2-dimethyl-6beta-(phenylacetamido)penam-3alpha-carboxylate
2,2-dimethyl-6beta-(phenylacetamido)penam-3alpha-carboxylic acid
4-27-00-05861 (Beilstein Handbook Reference)
46609_FLUKA
46609_RIEDEL
6-(2-phenylacetamido)Penicillanate
6-(2-phenylacetamido)penicillanic acid
6-(2-phenylacetamido)Penicillanic acid
6-(2-Phenylacetamido)penicillanic acid
61-33-6
69-57-8 (mono-hydrochloride salt)
AB00384263
Abbocillin
AC-14408
AC1L1LDX
AC1LD0NQ
AC1Q2CBJ
Antibioticos brand OF penicillin g sodium
AR-1K9813
Ayercillin
Bencilpenicilina
Bencilpenicilina [Spanish]
Benpen
bensylpenicillin
Bensylpenicillin
Benzopenicillin
benzyl benicillin
Benzyl benicillin
Benzyl penicillin
Benzyl-6-aminopenicillinic acid
Benzylpenicillin
Benzylpenicillin (INN)
Benzylpenicillin [INN:BAN]
Benzylpenicillin G
Benzylpenicillin potassium
Benzylpenicillin potassium (JP15)
Benzylpenicillin potassium salt
Benzylpenicillinate
Benzylpenicilline
Benzylpénicilline
Benzylpenicilline [French]
benzylpenicilline potassique
Benzylpenicillinic acid
Benzylpenicillinum
Benzylpenicillinum [Latin]
Bicillin
Bicillin (*Benzathine Salt, Tetrahydrate*)
Bio-0602
Bioniche brand OF penicillin g sodium
BPBio1_001206
BRD-K55191674-236-03-7
BRD-K55191674-237-02-7
Britannia brand OF penicillin g sodium
BRN 0044740
BSPBio_001096
BSPBio_002183
C05551
C16H18N2O4S
CEPA brand OF penicillin g sodium
CHEBI:18208
CHEBI:51354
CHEBI:7963
CHEMBL1223
CHEMBL29
CID443084
CID5904
CID640429
Cillora
Cilloral
Cilopen
Clonmel brand OF penicillin g sodium
Coliriocilina
Compocillin G
Cosmopen
Crystapen
Crysticillin 300 A.S.
CSL Brand OF penicillin g sodium
D01053
D02336
DB01053
DivK1c_000316
Dropcillin
EINECS 200-506-3
Ern brand OF penicillin g sodium
Free benzylpenicillin
Free penicillin G
Free penicillin II
Galofak
Gelacillin
Grünenthal brand OF penicillin g potassium
HMS1920F12
HMS2091N12
HMS500P18
HSDB 3166
|
I06-1083
IDI1_000316
Jenapharm brand OF penicillin g sodium
KBio1_000316
KBio2_001413
KBio2_003981
KBio2_006549
KBio3_001683
KBioGR_000942
KBioSS_001413
Lakeside brand OF penicillin g sodium
Liquacillin
Llorente brand OF penicillin g sodium
LS-149836
LS-195224
Medical brand OF penicillin g potassium
Medical brand OF penicillin g sodium
Megacillin
MLS000069426
MLS000766897
MLS001032123
MLS001076462
MLS001173382
MolPort-002-511-679
MolPort-003-666-255
NCGC00021679-03
NCGC00021679-04
NCGC00159348-02
nchembio.177-comp1
NChemBio.2007.21-comp4
nchembio.252-comp1
NINDS_000316
Normon brand OF penicillin g sodium
NSC 193396
Or-pen
Ortega brand OF penicillin g potassium
P1772
P7794_SIGMA
P8721_SIAL
Parcillin
Parmed brand OF penicillin g potassium
PCG
Pekamin
Pencillin G
Pengesod
Penibiot
Penicilina g llorente
Penicillin
penicillin g
Penicillin G
Penicillin g jenapharm
Penicillin g potassium
Penicillin G potassium
Penicillin G potassium (USP)
Penicillin G potassium salt
Penicillin g sodium
Penicillin grünenthal
Penicillin potassium G, crystalline
PENICILLIN-G
Penicillin-G potassium
Penilevel
Peniroger
PENK_SIAL
PENK_SIGMA
Pfizer brand OF penicillin g potassium
Pfizerpen
Pfizerpen (TN)
PG
Pharmacillin
Phenylacetamidopenicillanic acid
Phenylacetyl-6-aminopenicillanic acid
PNN
potassium 2,2-dimethyl-6beta-(phenylacetamido)penam-3alpha-carboxylate
Pradupen
Prestwick0_001078
Prestwick1_001078
Prestwick2_001078
Prestwick3_001078
SMR000059004
SMR000538912
Sodiopen
Sodipen
Sodium benzylpenicillin
Sodium penicillin
SPBio_000475
SPBio_002998
Specilline G
Spectrum_000933
SPECTRUM1500465
Spectrum2_000518
Spectrum3_000542
Spectrum4_000471
Spectrum5_001108
ST51052951
UCB brand OF penicillin g sodium
Unicilina
UNII-Q42T66VG0C
Ursopen
Vangard brand OF penicillin g potassium
Van-pen-g
ZINC03871701
|
|
| 33 |
|
Fentanyl |
Approved, Illicit, Investigational, Vet_approved |
Phase 3 |
|
437-38-7 |
3345
|
|
Synonyms:
1-Phenethyl-4-(N-phenylpropionamido)piperidine
1-phenethyl-4-N-propionylanilinopiperidine
1-Phenethyl-4-N-propionylanilinopiperidine
437-38-7
5-22-08-00049 (Beilstein Handbook Reference)
80832-90-2
990-73-8 (citrate)
AC1L1FQ2
Actiq
BIDD:GT0555
BRN 0494484
Cephalon brand OF fentanyl buccal oravescent
CHEBI:119915
CHEMBL596
CID3345
D00320
DB00813
Duragesic
Duragesic (TN)
Duragesic-100
Duragesic-12
Duragesic-25
Duragesic-50
Duragesic-75
Durogesic
EINECS 207-113-6
Fentanest
Fentanil
Fentanil [DCIT]
Fentanila
Fentanila [INN-Spanish]
Fentanilo
fentanyl
Fentanyl
Fentanyl (JAN/USAN/INN)
Fentanyl [INN:BAN]
Fentanyl CII
Fentanyl citrate
Fentanyl-100
Fentanyl-12
Fentanyl-25
Fentanyl-50
|
Fentanyl-75
Fentanylum
Fentanylum [INN-Latin]
Fentora
HSDB 3329
IONSYS
Janssen pharmaceutica brand OF fentanyl
JNS020QD
L001275
LS-124439
Matrifen
MolPort-003-847-369
N-(1-phenethyl-4-piperidinyl)-N-phenylpropionamide
N-(1-Phenethyl-4-piperidinyl)-N-phenylpropionamide
N-(1-phenethyl-4-piperidyl)propionanilide
N-(1-Phenethyl-4-piperidyl)propionanilide
N-(1-phenethylpiperidin-4-yl)-N-phenylpropanamide
N-(1-phenethylpiperidin-4-yl)-N-phenylpropionamide
N-(1-Phenethylpiperidin-4-yl)-N-phenylpropionamide
N-(1-Phenethyl-piperidin-4-yl)-N-phenyl-propionamide
Nasalfent
NCGC00168252-01
N-phenethyl-4-(N-propionylanilino)piperidine
N-Phenethyl-4-(N-propionylanilino)piperidine
N-phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)propanamide
N-Phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)propanamide
N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide
Oprea1_152073
Oprea1_207148
PDSP1_000860
PDSP2_000846
Pentanyl
Phentanyl
Propanamide, N-phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)- (9CI)
R 4263
Rapinyl
Sentonil
Sublimase
Sublimaze
Transmucosal oral fentanyl citrate
UNII-UF599785JZ
|
|
| 34 |
|
Fluconazole |
Approved, Investigational |
Phase 2, Phase 3 |
|
86386-73-4 |
3365
|
|
Synonyms:
2-(2,4-difluorophenyl)-1,3-bis(1,2,4-triazol-1-yl)propan-2-ol
2-(2,4-Difluorophenyl)-1,3-bis(1H-1,2,4-triazol-1-yl)-2-propanol
2-(2,4-Difluorophenyl)-1,3-bis(1H-1,2,4-triazol-1-yl)propan-2-ol
2-(2,4-Difluoro-phenyl)-1,3-bis-[1,2,4]triazol-1-yl-propan-2-ol
2-(2,4-DIFLUOROPHENYL)-1,3-di(1H-1,2,4-triazol-1-yl)propan-2-ol
2-(2,4-DIFLUOROPHENYL)-1,3-DI(1H-1,2,4-TRIAZOL-1-YL)PROPAN-2-OL
2-(2,4-Difluorophenyl)-1,3-di-1H-1,2,4-triazol-1-ylpropan-2-ol
2,4-difluoro-,1-bis(1H-1,2,4-triazol-1-ylmethyl)benzyl alcohol
2,4-difluoro-a,a-Bis(1H-1,2,4-triazol-1-ylmethyl)benzyl alcohol
2,4-difluoro-alpha,alpha-Bis(1H-1,2,4-triazol-1-ylmethyl)benzyl alcohol
2,4-Difluoro-alpha,alpha-bis(1H-1,2,4-triazol-1-ylmethyl)benzyl alcohol
2,4-difluoro-α,α-bis(1H-1,2,4-triazol-1-ylmethyl)benzyl alcohol
86386-73-4
AbZ brand OF fluconazole
AbZ Brand of Fluconazole
AC1L1FRQ
AC1Q77FV
AC-428
Afungil
AKOS000280854
Alflucoz
Aliud brand OF fluconazole
Aliud Brand of Fluconazole
Alpharma brand OF fluconazole
Alpharma Brand of Fluconazole
apo Fluconazole
Apo Fluconazole
apo-Fluconazole
Apo-Fluconazole
Apotex brand OF fluconazole
Apotex Brand of Fluconazole
Armstrong brand OF fluconazole
Armstrong Brand of Fluconazole
Baten
Beagyne
Béagyne
betapharm Brand of Fluconazole
Betapharm brand OF fluconazole
BIDD:GT0799
Bio-0041
Biocanol
Biozole
Biozolene
BRD-K05977355-001-02-6
BSPBio_003504
C13H12F2N6O
Canzol
CCRIS 7211
CHEBI:46081
CHEMBL106
Chemia brand OF fluconazole
Chemia Brand of Fluconazole
CID3365
CPD000471882
Cryptal
ct Arzneimittel Brand of Fluconazole
CT Arzneimittel brand OF fluconazole
ct-Arzneimittel Brand of Fluconazole
CT-Arzneimittel brand OF fluconazole
D00322
D015725
DB00196
Diflazon
Diflucan
Diflucan (TN)
DIFLUCAN IN DEXTROSE 5% IN PLASTIC CONTAINER
DIFLUCAN IN SODIUM CHLORIDE 0.9%
DIFLUCAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Diflucan, Trican, Alfumet, Fluconazole
Difluconazole
Dimycon
DivK1c_001030
DRG-0005
Effik brand OF fluconazole
Effik Brand of Fluconazole
Elazor
F0677
F8929_SIGMA
FCZ
FLCZ
Fluc hexal
Fluc Hexal
Flucazol
Flucobeta
FlucoLich
Fluconazol
Fluconazol [Spanish]
Fluconazol abz
Fluconazol AbZ
Fluconazol al
Fluconazol AL
Fluconazol isis
Fluconazol Isis
Fluconazol ratiopharm
Fluconazol stada
Fluconazol Stada
Fluconazol von ct
Fluconazol von CT
fluconazole
Fluconazole & Bovine Lactoferrin
Fluconazole & hGCSF
Fluconazole & Human recombinant granulocyte colony stimulating factor
Fluconazole & MC-510,011
Fluconazole (JAN/USAN/INN)
Fluconazole [USAN:INN:BAN:JAN]
Fluconazole in combination with MGCD290
|
Fluconazole in dextrose 5% in plastic container
Fluconazole in sodium chloride 0.9%
Fluconazole in sodium chloride 0.9% in plastic container
Fluconazol-isis
Fluconazol-Isis
Fluconazol-ratiopharm
Fluconazolum
Fluconazolum [Latin]
Flucostat
Flucytosine & Nyotran
Flucytosine & Nyotran(Liposomal Nystatin)
Flukezol
Flunazul
Flunizol
Fluzone
Forcan
Fuconal
Fungata
GL663142 & Fluconazole
Hexal brand OF fluconazole
Hexal Brand of Fluconazole
HMS1922O10
HMS2090I20
HMS2093M21
HMS503M21
HSDB 7420
I06-0069
IDI1_001030
KBio1_001030
KBio2_002134
KBio2_004702
KBio2_007270
KBio3_003009
KBioGR_000360
KBioSS_002134
KS-1059
Lavisa
Lesvi brand OF fluconazole
Lesvi Brand of Fluconazole
Lichtenstein brand OF fluconazole
Lichtenstein Brand of Fluconazole
Loitin
LS-1858
Mack brand OF fluconazole
Mack Brand of Fluconazole
MLS001066394
MLS001165780
MLS001195645
MLS001304713
MLS001306492
MolPort-000-883-859
MolPort-002-885-825
Mutum
NCGC00095089-01
NCGC00095089-02
NCGC00095089-04
NCGC00095089-05
nchembio.100-comp3
nchembio.65-comp15
Neofomiral
NINDS_001030
Oxifugol
Oxifungol
Pfizer brand OF fluconazole
Pfizer Brand of Fluconazole
Pfleger brand OF fluconazole
Pfleger Brand of Fluconazole
Pritenzol
ratiopharm Brand of Fluconazole
Ratiopharm brand OF fluconazole
S1331_Selleck
SAM002589905
SAT brand OF fluconazole
SAT Brand of Fluconazole
Silanes brand OF fluconazole
Silanes Brand of Fluconazole
SMR000471882
Solacap
SPBio_001613
Spectrum_001654
SPECTRUM1503975
Spectrum2_001607
Spectrum3_001912
Spectrum4_000090
Spectrum5_001277
Stada brand OF fluconazole
Stada Brand of Fluconazole
STK619301
Syscan
TL8005609
TPF
Triflucan
UK 49858
UK49858
UK-49858
UNII-8VZV102JFY
Vita brand OF fluconazole
Vita Brand of Fluconazole
XMP.284 & Fluconazole
XMP.366 & Fluconazole
XMP.391 & Fluconazole
Zemyc
ZINC00004009
Zoltec
Zonal
|
|
| 35 |
|
Miconazole |
Approved, Investigational, Vet_approved |
Phase 2, Phase 3,Phase 1 |
|
22916-47-8 |
4189
|
|
Synonyms:
(+-)-1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl) imidazole
1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-[2-(2,4-dichlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole
1-[2-(2,4-Dichloro-benzyloxy)-2-(2,4-dichloro-phenyl)-ethyl]-1H-imidazole
1-[2-(2,4-Dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]-1H-imidazole
1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole
1-[2-(2,4-dichlorophenyl)-2-{[(2,4-dichlorophenyl)methyl]oxy}ethyl]-1H-imidazole
1-[2,4-Dichloro- beta-([2,4-dichloro- benzyl]oxy)phenethyl]imidazole
1-{2-[(2,4-dichlorobenzyl)oxy]-2-(2,4-dichlorophenyl)ethyl}-1H-imidazole
22832-87-7 (NITRATE)
22916-47-8
75319-47-0
AB00053500
AC1L1HM1
Aflorix(nitrate)
AKOS001574474
Albistat(nitrate)
Andergin(nitrate)
BPBio1_000279
BRD-A82396632-001-03-0
BRD-A82396632-008-02-7
Brentan
BRN 0965511
BSPBio_000253
BSPBio_002033
CCRIS 7924
CHEBI:6923
CHEMBL91
CID4189
Conofite(nitrate)
CPD-4501
D00416
Dactarin
Daktarin iv
Daktarin IV
DB01110
DivK1c_000156
EINECS 245-324-5
Epi-Monistat(nitrate)
Esteve brand OF miconazole
Femizol-M
Florid(nitrate)
Gyno-Daktar(nitrate)
HMS1568M15
HMS2090B21
I14-14342
IDI1_000156
imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl) methoxy)ethyl)- (9CI)
Imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl)methoxy)ethyl)- (9CI)
Janssen cilag brand OF miconazole
Janssen-cilag brand OF miconazole
Johnston and johnston brand OF miconazole nitrate
KBio1_000156
KBio2_001445
KBio2_004013
KBio2_006581
KBio3_001533
KBioGR_000581
KBioSS_001445
Lotrimin AF(nitrate)
LS-78378
MCZ
Micantin (nitrate)
Miconasil nitrate
Miconasil Nitrate
Miconazol
|
Miconazol [INN-Spanish]
miconazole
Miconazole
Miconazole (JP15/USP/INN)
Miconazole [USAN:BAN:INN:JAN]
Miconazole 3
Miconazole 3 Combination Pack
Miconazole 7 Combination Pack
Miconazole esteve brand
Miconazole janssen-cilag brand
Miconazole nitrate
Miconazole nitrate salt
Miconazole-7
Miconazolo
Miconazolo [DCIT]
Miconazolum
Miconazolum [INN-Latin]
Micozole
Minostate
MJR 1762
MLS002222203
MolPort-002-557-553
Monazole 7
Monista (nitrate)
Monistat
Monistat (TN)
Monistat 1 Combination Pack
Monistat 3 Dual-Pak
Monistat 3 Vaginal Ovules
Monistat 5 Tampon
Monistat 7 Dual-Pak
Monistat 7 Vaginal Suppositories
Monistat Dual- PAK
Monistat IV
Monistat iv (tn)
Monistat iv (TN)
Monistat-Derm
NCI60_001353
NCI60_001380
NINDS_000156
Nitrate, miconasil
Nitrate, miconazole
Novo-Miconazole Vaginal Ovules
NSC 170986
NSC169434
NSC170986
Oprea1_091955
Prestwick_335
Prestwick0_000067
Prestwick1_000067
Prestwick2_000067
Prestwick3_000067
R 18134
R-14,889
SMR001307249
SPBio_000976
SPBio_002174
Spectrum_000965
Spectrum2_001048
Spectrum3_000507
Spectrum4_000061
Spectrum5_001297
STK834405
STOCK1S-93556
UNII-7NNO0D7S5M
Vusion
Zimycan
|
|
| 36 |
|
Cevimeline |
Approved |
Phase 3 |
|
107233-08-9 |
83898
25137844
|
|
Synonyms:
(+-)-cis-2-Methylspiro(1,3-oxathiolane-5,3'-quinuclidine) hydrochloride, hemihydrate
(+/-)cis-2-methylspiro(1-azabicyclo[2.2.2]octance-3,5'-(1,3)oxathiolane) hydrochloride hemihydrate
(2R,2'R)-2'-methylspiro[4-azabicyclo[2.2.2]octane-2,5'-[1,3]oxathiolane] dihydrochloride hydrate
(2R,5R)-2-methylspiro[1,3-oxathiolane-5,3'-1-azabicyclo[2.2.2]octane]
(2R,5R)-2-methylspiro[1,3-oxathiolane-5,3'-1-azabicyclo[2.2.2]octane] dihydrate hydrochloride
(2R,5R)-2-methylspiro[1,3-oxathiolane-5,3'-1-azabicyclo[2.2.2]octane] hydrate dihydrochloride
(2R,5R)-2-methylspiro[1,3-oxathiolane-5,3'-1-azabicyclo[2.2.2]octane] hydrate hydrochloride
107233-08-9
153504-70-2
2-methyspiro(1,3-Oxathiolane-5,3)quinuclidine
2-Methyspiro(1,3-oxathiolane-5,3)quinuclidine
AC1L36EF
AC1L36GD
AC1NR4MS
AC1OCEXD
AF 102b
AF 102B
AF 102b, (cis-(+))-isomer
AF 102b, (trans)-isomer
AF-102b
AF102B
AF-102B
BIDD:GT0265
C10H17NOS
Cevimelina
Cevimeline
Cevimeline (INN)
Cevimeline [INN]
Cevimeline HCl 1/2H2O
Cevimeline hydrochloride
Cevimeline hydrochloride (USAN)
Cevimeline hydrochloride [USAN]
Cevimeline hydrochloride hemihydrate
|
cevimeline hydrochloride hydrate
Cevimeline hydrochloride hydrate
Cevimeline hydrochloride hydrate (JAN)
Cevimeline.HCl
Cevimelinum
CHEMBL1200362
CID5284532
CID6918023
CID83898
CID83927
cis-2-Methylspiro(1,3-oxathiolane-5,3')quinuclidine hydrochloride hydrate (2:2:1)
D00661
D07667
DB00185
Evoxac
Evoxac (TN)
Fks 508
FKS 508
FKS-508
HSDB 7286
LS-145782
LS-172037
NCGC00181793-01
Saligren
Saligren (TN)
SND 5008, AF-102B, FKS-508
SND-5008
Sni 2011
SNI-2011
SNK-508
UNII-K9V0CDQ56E
UNII-P81Q6V85NP
|
|
| 37 |
|
Megestrol acetate |
Approved, Investigational, Vet_approved |
Phase 3 |
|
595-33-5 |
11683
|
|
Synonyms:
17-Acetoxy-6-methylpregna-4,6-diene-3,20-dione
17alpha-Acetoxy-6-dehydro-6-methylprogesterone
17alpha-Hydroxy-6-methylpregna-4,6-diene-3,20-dione acetate
17-Hydroxy-6-methylpregna-4,6-diene-3,20-dione 17-acetate
17α-Acetoxy-6-dehydro-6-methylprogesterone
17α-Hydroxy-6-methylpregna-4,6-diene-3,20-dione acetate
6-Dehydro-6-methyl-17alpha-acetoxyprogesterone
6-Dehydro-6-methyl-17α-acetoxyprogesterone
6-Methyl-17alpha-acetoxypregna-4,6-diene-3,20-dione
6-Methyl-17alpha-hydroxy-delta(sup 6)-progesterone acetate
|
6-Methyl-17α-acetoxypregna-4,6-diene-3,20-dione
6-Methyl-17α-hydroxy-delta(sup 6)-progesterone acetate
6-Methyl-6-dehydro-17alpha-acetoxyprogesterone
6-Methyl-6-dehydro-17α-acetoxyprogesterone
6-Methyl-delta(sup 4,6)-pregnadien-17alpha-ol-3,20-dione acetate
6-Methyl-delta(sup 4,6)-pregnadien-17α-ol-3,20-dione acetate
6-Methyl-delta(sup 6)-dehydro-17alpha-acetoxyprogesterone
6-Methyl-delta(sup 6)-dehydro-17α-acetoxyprogesterone
Megace
MGA
|
|
| 38 |
|
Histamine |
Approved, Investigational |
Phase 3,Phase 2 |
|
51-45-6, 75614-87-8 |
774
|
|
Synonyms:
.beta.-Imidazolyl-4-ethylamine
[3H]histamine
1avn
1H-Imidazole-4-ethanamine
1H-Imidazole-5-ethanamine
1qft
2-(1H-imidazol-4-yl)ethan-1-amine
2-(1H-Imidazol-4-yl)ethanamine
2-(1H-Imidazol-4-yl)ethylamine
2-(1H-imidazol-5-yl)ethanamine
2-(1H-Imidazol-5-yl)ethanamine
2-(1H-Imidazol-5-yl)ethylamine
2-(3H-Imidazol-4-yl)-ethylamine
2-(4-Imidazolyl)ethanamine
2-(4-imidazolyl)ethylamine
2-(4-Imidazolyl)ethylamine
2-[4-Imidazolyl]ethylamine
2-Imidazol-4-ylethylamine
2-Imidazol-4-yl-ethylamine
4-(2-Aminoethyl)-1H-imidazole
4-(2-Aminoethyl)imidazole
4-imidazoleethylamine
4-Imidazoleethylamine
51-45-6
53290_FLUKA
5-imidazoleethylamine
5-Imidazoleethylamine
64422-25-9
924364-91-0
AC-13185
AC1L19ZT
AC1Q54BV
AC1Q54BW
AKOS000274386
ALBB-005968
BCBcMAP01_000250
beta-aminoethylglyoxaline
beta-Aminoethylglyoxaline
beta-aminoethylimidazole
beta-Aminoethylimidazole
beta-aminothethylglyoxaline
beta-Aminothethylglyoxaline
beta-Imidazolyl-4-ethylamine
b-Imidazolyl-4-ethylamine
Bio1_000487
Bio1_000976
Bio1_001465
Bio2_000389
Bio2_000869
bmse000744
BSPBio_001117
BSPBio_002124
C00388
CCRIS 6535
Ceplene
CHEBI:18295
CHEMBL90
CID774
D08040
Dihydrochloride, histamine
DivK1c_000308
EINECS 200-100-6
Eramin
Ergamine
Ergotidine
F411C768-A159-4FC0-A195-291A08BB03AA
Free histamine
H7125_SIGMA
histamine
Histamine (DCF)
|
Histamine [USAN]
Histamine Base
Histamine dihydrochloride
Histamine hydrochloride
Histamine, Free Base
Histaminum
Histaminum (TN)
HMS1362G19
HMS1792G19
HMS1990G19
HSDB 3338
HSM
Hydrochloride, histamine
IDI1_000308
IDI1_002144
Imidazole-4-ethylamine
Istamina
Istamina [Italian]
KBio1_000308
KBio2_000457
KBio2_001325
KBio2_003025
KBio2_003893
KBio2_005593
KBio2_006461
KBio3_000853
KBio3_000854
KBio3_001344
KBioGR_000457
KBioGR_001580
KBioSS_000457
KBioSS_001325
L000292
L-Histamin base
L-histamine
L-Histamine
Lopac0_000595
Lopac-H-7250
LS-75835
MLS000069447
MolPort-001-785-597
MolPort-002-042-264
NCGC00015513-01
NCGC00015513-08
NCGC00093371-02
NCGC00093371-03
NCGC00093371-04
NCGC00093371-05
nchembio.87-comp54
nchembio714-comp1
NINDS_000308
NSC 33792
NSC33792
Peremin
SDCCGMLS-0066601.P001
SMP1_000151
SMR000059091
SPBio_000729
Spectrum_000845
Spectrum2_000665
Spectrum3_000452
Spectrum4_000960
Spectrum5_000796
ST073926
STK346752
STOCK5S-55669
Theramine
UNII-820484N8I3
WLN: T5M CNJ D2Z
ZERO/004089
|
|
| 39 |
|
Doxepin |
Approved, Investigational |
Phase 3 |
|
1668-19-5 |
667477
667468
|
|
Synonyms:
(3E)-3-(6H-benzo[c][1]benzoxepin-11-ylidene)-N,N-dimethylpropan-1-amine
(3E)-3-dibenzo[b,e]oxepin-11(6H)-ylidene-N,N-dimethylpropan-1-amine
(3Z)-3-(6H-benzo[c][1]benzoxepin-11-ylidene)-N,N-di(methyl)propan-1-amine
(3Z)-3-(6H-benzo[c][1]benzoxepin-11-ylidene)-N,N-dimethylpropan-1-amine
(3Z)-3-dibenzo[b,e]oxepin-11(6H)-ylidene-N,N-dimethylpropan-1-amine
(Z)-Doxepin
11-(3-(Dimethylamino)propylidene)-6H-dibenz(b,e)oxepine
11-(3-Dimethylamino-propyliden)-6,11-dihydro-dibenz(b,e)oxipin
11-(3-Dimethylaminopropylidene)-6,11-dihydrodibenz(b,e)oxipin
1668-19-5
3-(6H-benzo[c][1]benzoxepin-11-ylidene)-N,N-dimethylpropan-1-amine
3607-18-9
3-Dibenz[b,e]oxepin-11(6H)-ylidene-N,N-dimethyl-1-propanamine
3-dibenzo[b,e]oxepin-11(6H)-ylidene-N,N-dimethylpropan-1-amine
AC1L1FAW
AC1LDI5F
AC1LDI63
AC1NUW4A
Adapin
AKOS001582771
apo Doxepin
apo-Doxepin
ApoDoxepin
Aponal
BPBio1_000118
BRD-K36616567-003-01-5
BRD-K37694030-003-02-8
BRD-K54462405-003-03-3
BSPBio_000106
BSPBio_001934
C06971
C19H21NO
CAS-1229-29-4
CCRIS 9176
CHEBI:36691
CHEBI:36692
CHEBI:4710
CHEMBL101740
CID10039438
CID3158
CID5462131
CID667468
CID667477
Cidoxepin
Cidoxepin [INN]
Cidoxepina
Cidoxepinum
cis-doxepin
cis-N-(3-(6H-Dibenz(b,e)oxepin-11-yliden)propyl)-N,N-dimethylamin
Curatin
D07875
DB01142
Deptran
Desidox
DivK1c_000431
Doneurin
Doxepia
doxepin
Doxepin
Doxepin (INN)
Doxepin (Z)-isomer
Doxepin [USAN]
Doxepin beta
Doxepin Hcl
Doxepin hydrochloride
|
Doxepin Hydrochloride,
Doxepin hydrochloride, cis-trans isomer mixture (approximately 1:5)
Doxepin RPH
Doxepin, Hydrochloride
Doxepina
Doxepina [INN-Spanish]
Doxepine
Doxepin-RPH
Doxepinum
Doxepinum [INN-Latin]
Espadox
HSDB 3069
Hydrochloride, doxepin
IDI1_000431
KBio1_000431
KBio2_001285
KBio2_003853
KBio2_006421
KBio3_001154
KBioGR_001131
KBioSS_001285
L000699
Lopac0_000339
Lopac-D-4526
LS-174582
LS-61638
Mareen
MF 10
MOLI001594
MolPort-003-847-024
MolPort-005-933-834
N,N-Dimethyldibenz(b,e)oxepin-delta(11(6H),gamma)-propylamine
NCGC00015344-01
NCGC00015344-02
NCGC00015344-04
NCGC00024623-01
NCGC00024623-02
NCGC00162127-01
NINDS_000431
novo Doxepin
novo-Doxepin
Oprea1_473232
Prestwick0_000263
Prestwick1_000263
Prestwick2_000263
Prestwick3_000263
Prudoxin
Quitaxon
Sinequan
Sinequan (TN)
Sinquan
SPBio_000206
SPBio_002325
Spectrum_000805
Spectrum2_000133
Spectrum3_000407
Spectrum4_000526
Spectrum5_001051
Tocris-0508
Triadapin
UNII-5ASJ6HUZ7D
UNII-F96TTB8728
Xepin
Zonalon
|
|
| 40 |
|
Cisplatin |
Approved |
Phase 3,Phase 2,Phase 1,Not Applicable |
|
15663-27-1 |
2767
441203
84093
|
|
Synonyms:
(SP-4-1)-diamminedichloridoplatinum
(SP-4-1)-diamminedichloroplatinum
(SP-4-2)-diamminedichloridoplatinum
(SP-4-2)-diamminedichloroplatinum
Abiplatin
Biocisplatinum
Briplatin
CACP
Carboquone
CDDP
CHEBI:35852
CID441203
Cis Pt II
cis-[PtCl2(NH3)2]
cis-DDP
Cis-DDP
Cis-Diaminedichloroplatinum
cis-diamminedichloridoplatinum(II)
cis-Diamminedichloroplatinum
Cis-Diamminedichloroplatinum
cis-diamminedichloroplatinum(II)
cis-Dichlorodiammineplatinum(II)
Cismaplat
Cisplatine
cisplatino
Cisplatino
Cisplatinum
Cisplatyl
Citoplationo
CPD0-1392
CPDC
|
CPDD
DB00515
DDP
DDPT
Diamminedichloroplatinum
EU-0100918
Lederplatin
nchembio773-comp1
Neoplatin
Peyrone's chloride
Peyrone's salt
Plastin
Platamine
Platiblastin
Platidiam
Platinex
Platinol
Platinol-AQ
Platinoxan
Platinum Ammine Chloride
Platinum Ammonium Chloride
Platinum Diamine Dichloride
Randa
trans-DDP
Trans-DDP
Trans-Diaminedichloroplatinum
trans-diamminedichloridoplatinum(II)
Trans-Diamminedichloroplatinum
Trans-Dichlorodiammine Platinum
Trans-Platinumdiammine Dichloride
|
|
| 41 |
|
Fluorouracil |
Approved |
Phase 3,Phase 2,Phase 1 |
|
51-21-8 |
3385
|
|
Synonyms:
1004-03-1
1-fluoro-1h-pyrimidine-2,4-dione
1upf
2,4-Dihydroxy-5-fluoropyrimidine
2,4-Dioxo-5-fluoropryimidine
2,4-Dioxo-5-fluoropyrimidine
47576_FLUKA
4921-97-5
5 Fluorouracil
5 Fluorouracil biosyn
5 FU lederle
5 FU Lederle
5 FU medac
5 HU hexal
5 HU Hexal
51-21-8
5-Faracil
5-Fluor-2,4(1H,3H)-pyrimidindion
5-Fluor-2,4(1H,3H)-pyrimidindion [Czech]
5-Fluor-2,4-dihydroxypyrimidin
5-Fluor-2,4-dihydroxypyrimidin [Czech]
5-Fluor-2,4-pyrimidindiol
5-Fluor-2,4-pyrimidindiol [Czech]
5-Fluoracil
5-Fluoracil [German]
5-Fluoracyl
5-fluoro uracil
5-fluoro-1H-pyrimidine-2,4-dione
5-Fluoro-2,4(1H,3H)-pyrimidinedione
5-Fluoro-2,4-pyrimidinedione
5-Fluoropyrimidin-2,4-diol
5-fluoropyrimidine-2,4(1H,3H)-dione
5-Fluoropyrimidine-2,4-dione
5-fluorouracil
5-Fluorouracil
5-Fluorouracil-biosyn
5-Fluoruracil
5-Fluoruracil [German]
5-Fluracil
5-Ftouracyl
5FU
5-FU
5-FU (TN)
5-FU lederle
5-FU Lederle
5-FU medac
5-HU hexal
5-HU Hexal
79108-01-3
AC-11201
AC1L1FTE
AC1Q4N2X
AccuSite
Actino-Hermal
Adrucil
Adrucil (TN)
AI3-25297
AKOS000119162
AKOS003237897
Allergan brand OF fluorouracil
Allergan Brand of Fluorouracil
Arumel
BB_NC-0576
biosyn Brand of Fluorouracil
Biosyn brand OF fluorouracil
BSPBio_002048
C07649
C4H3FN2O2
Carac
Carac (TN)
Carzonal
CCRIS 2582
CHEBI:46345
CHEMBL185
CID3385
Cinco FU
CPD000038082
CPD0-1327
CSP Brand of Fluorouracil
CSP Brand OF fluorouracil
Cytosafe
D005472
D00584
Dakota brand OF fluorouracil
Dakota Brand of Fluorouracil
Dakota, fluorouracile
Dakota, Fluorouracile
DB00544
Dermatech brand OF fluorouracil
Dermatech Brand of Fluorouracil
Dermik brand OF fluorouracil
Dermik Brand of Fluorouracil
DivK1c_000054
Effluderm
Effluderm (free base)
Efudex
Efudix
Efurix
EINECS 200-085-6
EU-0100536
F 6627
F0151
F6627_SIGMA
F8423_SIGMA
Ferrer brand OF fluorouracil
Ferrer Brand of Fluorouracil
Fiverocil
Fluoro Uracil
fluoro Uracile icn
Fluoro Uracile ICN
Fluoroblastin
Fluoroplex
Fluoroplex (TN)
fluorouracil
Fluorouracil
Fluorouracil (JP15/USP/INN)
Fluorouracil [USAN:INN:BAN:JAN]
Fluorouracil gry
Fluorouracil GRY
Fluorouracil mononitrate
Fluorouracil Mononitrate
Fluorouracil monopotassium salt
Fluorouracil Monopotassium Salt
Fluorouracil monosodium salt
Fluorouracil Monosodium Salt
Fluorouracil potassium salt
Fluorouracil Potassium Salt
Fluorouracil teva brand
Fluorouracil Teva Brand
Fluorouracile
Fluoro-uracile
Fluorouracile [DCIT]
|
Fluorouracile dakota
Fluorouracile Dakota
fluoro-Uracile icn
Fluoro-Uracile ICN
Fluorouracil-gry
Fluorouracil-GRY
Fluorouracilo
Fluoro-uracilo
Fluorouracilo [INN-Spanish]
fluorouracilo Ferrer far
Fluorouracilo Ferrer Far
Fluorouracilum
Fluorouracilum [INN-Latin]
Fluoruracil
Fluouracil
Flurablastin
Fluracedyl
Fluracil
Fluracilum
Fluri
Fluril
Fluro Uracil
Fluroblastin
Flurodex
Flurouracil
Flurox
FT-0082524
Ftoruracil
FU
Gry brand OF fluorouracil
Gry Brand of Fluorouracil
haemato Brand OF fluorouracil
Haemato Brand of Fluorouracil
haemato Fu
Haemato fu
haemato-Fu
Haemato-fu
Hexal brand OF fluorouracil
Hexal Brand of Fluorouracil
HMS1920O18
HMS2090I04
HMS2091F19
HMS500C16
HSDB 3228
I07-0022
ICN brand OF fluorouracil
ICN Brand of Fluorouracil
IDI1_000054
IN1335
inhibits thymilidate synthetase
KBio1_000054
KBio2_001321
KBio2_003889
KBio2_006457
KBio3_001268
KBioGR_001253
KBioSS_001321
Kecimeton
Lopac0_000536
Lopac-F-6627
LS-153
medac Brand of Fluorouracil
Medac brand OF fluorouracil
MLS000069498
MLS002415705
MolPort-000-156-102
MolPort-003-990-447
MolPort-004-758-143
MolPort-004-758-144
MolPort-005-861-486
NCGC00015442-01
NCGC00015442-03
NCGC00015442-10
NCGC00091349-01
NCGC00091349-02
NCGC00091349-03
NCGC00091349-04
NCGC00091349-05
NCGC00091349-07
NCGC00091349-08
nchembio.90-comp3
nchembio809-comp6
NCI60_001652
Neocorp brand OF fluorouracil
Neocorp Brand of Fluorouracil
Neofluor
NINDS_000054
NSC 19893
NSC19893
NSC-19893
Onkofluor
Onkoworks brand OF fluorouracil
Onkoworks Brand of Fluorouracil
Pharmachemie brand OF fluorouracil monosodium salt
Phthoruracil
Phtoruracil
Queroplex
Ribofluor
ribosepharm Brand of Fluorouracil
Ribosepharm brand OF fluorouracil
Riemser brand OF fluorouracil
Riemser Brand of Fluorouracil
Ro 2-9757
Ro-2-9757
Roche brand OF fluorouracil
Roche Brand of Fluorouracil
S1209_Selleck
SAM002264615
SMR000038082
SPBio_000291
Spectrum_000841
SPECTRUM1500305
Spectrum2_000076
Spectrum3_000434
Spectrum4_000557
Spectrum5_000718
STK297802
T5233394
tetratogen
Teva brand OF fluorouracil
Teva Brand of Fluorouracil
Timazin
TL8006093
U 8953
U-8953
Ulup
UNII-U3P01618RT
UPCMLD-DP130
UPCMLD-DP130:001
URF
WLN: T6MVMVJ EF
ZINC00897110
|
|
| 42 |
|
Docetaxel |
Approved, Investigational |
Phase 3,Phase 1,Phase 2 |
|
114977-28-5 |
148124
|
|
Synonyms:
(2alpha,5beta,7beta,10beta,13alpha)-4-(acetyloxy)-13-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7,10-trihydroxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate
(2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl (aR,bS)-b-[[(1,1-dimethylethoxy)carbonyl]amino]-a-hydroxybenzenepropanoate
01885_FLUKA
114977-28-5
4-(acetyloxy)-13alpha-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7beta,10beta-trihydroxy-9-oxo-5beta,20-epoxytax-11-en-2alpha-yl benzoate
AC1L3WHJ
AC-383
ANX-514
BIND-014
C11231
CHEBI:4672
CHEMBL92
CID148124
D07866
DB01248
docetaxel
Docetaxel
Docetaxel (INN)
docetaxel 114977-28-5
Docetaxel anhydrous
Docetaxel hydrate
Docetaxel trihydrate
Docetaxel, trihydrate
Docetaxel, Trihydrate
Docetaxol
|
EmDOC
HMS2089K08
InChI=1/C43H53NO14/c1-22-26(55-37(51)32(48)30(24-15-11-9-12-16-24)44-38(52)58-39(3,4)5)20-43(53)35(56-36(50)25-17-13-10-14-18-25)33-41(8,34(49)31(47)29(22)40(43,6)7)27(46)19-28-42(33,21-54-28)57-23(2)45/h9-18,26-28,30-33,35,46-48,53H,19-21H2,1-8H3,(H,44,5
MolPort-003-847-005
nchembio.188-comp8
nchembio.2007.34-comp7
nchembio.573-comp11
nchembio853-comp8
N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetylpaclitaxel
N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetylpaclitaxel
N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol
N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol
N-debenzoyl-N-Boc-10-deacetyl taxol
N-Debenzoyl-N-tert-butoxycarbonyl-10-deacetyltaxol
NSC-628503
PSMA-targeted docetaxel nanoparticle
RP-56976
SDP-014
Taxoltere metro
Taxotere
Taxotere (TN)
Taxotere(R)
TXL
XRP-6976L
|
|
| 43 |
|
Zinc |
Approved, Investigational |
Phase 3,Not Applicable |
|
7440-66-6 |
|
|
Synonyms:
alpha D Mannosidase
alpha D Mannoside mannohydrolase
alpha Mannosidase
alpha Mannosidase b
alpha-D-Mannosidase
alpha-D-Mannoside mannohydrolase
alpha-Mannosidase
alpha-Mannosidase, lysosomal
alpha-Mannosidase, neutral
Dietary zinc
LAMAN
Lysosomal alpha mannosidase
Lysosomal alpha-mannosidase
Mannohydrolase, alpha-D-mannoside
|
Mannosidase b, alpha
Neutral alpha mannosidase
Neutral alpha-mannosidase
Topostin b
Zinc cation
ZINC ion
Zinc, chelated
Zinc, elemental
Zinc, ion (ZN2+)
Zincum metallicum
Zn
ZN(2+)
ZN(II)
ZN2+
|
|
| 44 |
|
Zinc sulfate |
Approved, Investigational |
Phase 3,Not Applicable |
|
7733-02-0 |
|
|
Synonyms:
Zinc sulfate (anhydrous)
Zinc sulfate anhydrous
Zinc sulfate, anhydrous
|
Zinc sulphate anhydrous
Zinc sulphate, anhydrous
|
|
| 45 |
|
Pancreatic Polypeptide |
Investigational |
Phase 3 |
|
59763-91-6 |
|
| 46 |
|
Lapatinib |
Approved March 2007, Investigational |
Phase 3,Phase 2 |
|
388082-78-8, 231277-92-2 |
208908
9941095
|
|
Synonyms:
1xkk
231277-92-2
388082-78-8
4-[[3-Chloro-4-(3-fluorobenzyloxy)phenyl]amino]-6-[5-[[(2-methanesulfonylethyl)amino]methyl]furan-2-yl]quinazoline
AB1004631
AC-1314
AC1L4LL4
AKOS005145766
CHEBI:49603
CHEMBL1201179
CHEMBL554
CID11557040
CID208908
D04024
D08108
DB01259
DB02584
EN002712
FMM
GSK 572016
GSK572016
GW 572016
GW 572016X
GW2016
GW-2016
GW572016
GW-572016
GW-572016F
HMS2089H10
I01-1247
Kinome_3684
Kinome_3685
|
lapatinib
Lapatinib
Lapatinib (INN)
Lapatinib [INN]
lapatinib ditosylate
Lapatinib ditosylate
Lapatinib Ditosylate
Lapatinib ditosylate (USAN)
LAPATINIB DITOSYLATE MONOHYDRATE
Lapatinib tosilate hydrate
Lapatinib tosilate hydrate (JAN)
Lapatinib, Tykerb, GW572016
LS-187029
LS-187771
N-(3-chloro-4-(((3-Fluorobenzyl)oxy)phenyl)-6-(5-(((2-methylsulfonyl)ethyl)amino)methyl) -2-furyl)-4-quinazolinamine
N-(3-chloro-4-((3-Fluorophenyl)methoxy)phenyl)-6-(5-(((2-(methylsulfonyl)ethyl)amino)methyl)-2-furanyl)-4-quinazolinamine
N-(3-chloro-4-((3-Fluorophenyl)methoxy)phenyl)-6-(5-(((2-(methylsulphonyl)ethyl)amino)methyl)-2-furanyl)-4-quinazolinamine
N-(3-Chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-((2-methylsulfonylethylamino)methyl)-2-furyl)quinazolin-4-amine
N-(3-Chloro-4-{[(3-fluorophenyl)methyl]oxy}phenyl)-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furanyl]-4-quinazolinamine
N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]furan-2-yl]quinazolin-4-amine
N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine
N-{3-CHLORO-4-[(3-FLUOROBENZYL)OXY]PHENYL}-6-[5-({[2-(METHYLSULFONYL)ETHYL]AMINO}METHYL)-2-FURYL]-4-QUINAZOLINAMINE
N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulphonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine
NCGC00167507-01
nchembio866-comp20
NSC745750
TL80090051
Tycerb
Tykerb
Tykerb (TN)
Tyverb
UNII-0VUA21238F
|
|
| 47 |
|
Cola |
|
Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 |
|
|
|
| 48 |
|
Cytochrome P-450 Enzyme Inhibitors |
|
Phase 2, Phase 3 |
|
|
|
| 49 |
|
Trace Elements |
|
Phase 3,Phase 2,Phase 1,Not Applicable |
|
|
|
| 50 |
|
Pharmaceutical Solutions |
|
Phase 3,Phase 2,Not Applicable |
|
|
|
Interventional clinical trials:
(show top 50)
(show all 419)
| # |
Name |
Status |
NCT ID |
Phase |
Drugs |
| 1 |
Immunogenicity and Safety of Human Papilloma Virus Vaccine in Solid Organ Transplant Recipients |
Unknown status |
NCT02624349
|
Phase 4 |
Quadravalent human papillomavirus vaccine |
| 2 |
Does the HPV Vaccine Cause the Same Response in Adolescent Kidney and Liver Transplant Patients as in Healthy Controls? |
Unknown status |
NCT01101750
|
Phase 4 |
|
| 3 |
Use of Cidofovir for Recurrent Respiratory Papillomatosis |
Completed |
NCT00205374
|
Phase 4 |
Cidofovir;Placebo |
| 4 |
A Health Belief Model Based Intervention to Increase Human Papilloma Virus (HPV) Vaccination Among College Men |
Completed |
NCT01431079
|
Phase 4 |
|
| 5 |
Antisepsis Regimen in the Surgical Treatment of Human Papilloma Virus Generated Cervical Lesions: Polyhexamethylene Biguanide Versus Chlorhexidine |
Completed |
NCT01740245
|
Phase 4 |
|
| 6 |
Reactogenicity Study of Cervarix and Gardasil in UK Adolescent Girls |
Completed |
NCT00956553
|
Phase 4 |
|
| 7 |
Immune Response After Human Papillomavirus Vaccination in Patients With Autoimmune Disease |
Completed |
NCT00815282
|
Phase 4 |
|
| 8 |
Effectiveness, Safety and Immunogenicity of GSK Biologicals' HPV Vaccine GSK580299 (Cervarix TM) Administered in Healthy Adolescents |
Completed |
NCT00534638
|
Phase 4 |
|
| 9 |
MF59-adjuvanted Influenza Vaccine and 23-valent Pneumococcal Polysaccharide Vaccine |
Completed |
NCT02225327
|
Phase 4 |
|
| 10 |
Immunogenicity and Safety of PCV13 and Fluad in Adults Aged ≥60 Years |
Completed |
NCT02215863
|
Phase 4 |
|
| 11 |
Vaccination Against Human Papillomavirus (HPV) With the 9-valent Vaccine in HIV-positive Women (the Papillon Study) |
Recruiting |
NCT03391921
|
Phase 4 |
|
| 12 |
Intralesional Measles, Mumps, Rubella (MMR) Vaccine Versus Cryotherapy in Treatment of Multiple Common and Planter Warts |
Recruiting |
NCT03183765
|
Phase 4 |
Measles-Mumps-Rubella Vaccine |
| 13 |
HPV (Human Papilloma Virus) Vaccination After Treatment of Anal Intraepithelial Neoplasia (AIN) |
Active, not recruiting |
NCT02087384
|
Phase 4 |
Placebo |
| 14 |
Occupational Exposure to Human Papilloma Virus (HPV) and Prophylactic Vaccination |
Not yet recruiting |
NCT03350698
|
Phase 4 |
|
| 15 |
The Efficacy of Intra-lesional Bleomycin Versus Intra-lesional Purified Protein Derivative in Treatment of Palmoplantar Warts |
Not yet recruiting |
NCT03477448
|
Phase 4 |
Bleomycin;Purified Protein Derivative |
| 16 |
Interventional Cryotherapy for the Eradication of Benign Airway Disease ("ICE the BAD") |
Terminated |
NCT00747461
|
Phase 4 |
|
| 17 |
Anal Dysplasia Study of Men Who Have Sex With Men Living With HIV |
Withdrawn |
NCT01663558
|
Phase 4 |
imiquimod |
| 18 |
Two-dose Schedule of Quadrivalent HPV Recombinant Vaccine in 11-year-old Boys in Mexico City |
Unknown status |
NCT02382900
|
Phase 3 |
|
| 19 |
4-valent HPV Vaccine to Treat Recurrent Respiratory Papillomatosis in Children |
Unknown status |
NCT01995721
|
Phase 3 |
|
| 20 |
Protecting Young Special Risk Females From Cervical Cancer Through Human Papilloma Virus (HPV) Vaccination |
Completed |
NCT00964210
|
Phase 3 |
Licensed quadrivalent HPV vaccine, Gardasil |
| 21 |
Human Papilloma Virus (HPV) Vaccine Trial in Young Adolescent Women With GlaxoSmithKline Biologicals' (GSK Bio) HPV-16/18 Vaccine |
Completed |
NCT00316706
|
Phase 3 |
|
| 22 |
Human Papilloma Virus Vaccine Safety and Immunogenicity Trial in Young Adolescent Women With GSK Bio HPV-16/18. |
Completed |
NCT00196924
|
Phase 3 |
|
| 23 |
Human Papilloma Virus Vaccine Consistency and Non-inferiority Trial in Young Adult Women With GSK Bio HPV-16/18 |
Completed |
NCT00169494
|
Phase 3 |
|
| 24 |
Safety, Tolerability and Immunogenicity of HPV (Human Papilloma Virus) Vaccine in Healthy Females 9 to 15 Years of Age in India (V501-029) |
Completed |
NCT00380367
|
Phase 3 |
|
| 25 |
Human Papilloma Virus (HPV) Vaccine Efficacy Trial Against Cervical Pre-cancer in Young Adults With GlaxoSmithKline (GSK) Biologicals HPV-16/18 |
Completed |
NCT00122681
|
Phase 3 |
|
| 26 |
Human Papilloma Virus (HPV) Vaccine Immunogenicity and Safety Trial in Young and Adult Women With GSK Biologicals' HPV-16/18 |
Completed |
NCT00196937
|
Phase 3 |
|
| 27 |
Efficacy and Tolerability Study of V501 in Japanese Males (V501-122) |
Completed |
NCT01862874
|
Phase 3 |
|
| 28 |
Human Papillomavirus (HPV) Vaccine Consistency and Non-inferiority Trial in Young Adult Women |
Completed |
NCT00337818
|
Phase 3 |
|
| 29 |
A Study to Compare Immune Response of V503 to Gardasil in 16- to 26-year-old Men (V503-020) |
Completed |
NCT02114385
|
Phase 3 |
|
| 30 |
Effect of Vaccination in Patients With Recurrent Respiratory Papillomatosis |
Completed |
NCT01375868
|
Phase 3 |
|
| 31 |
Safety and Tolerability Study of V501 in Japanese Boys (V501-200) |
Completed |
NCT02576054
|
Phase 3 |
|
| 32 |
A Study to Evaluate the Safety, Immune Response, and Efficacy of Gardasil (V501, qHPV) in Mid-Adult Women (V501-019) |
Completed |
NCT00090220
|
Phase 3 |
|
| 33 |
Study to Evaluate the Immune Response and Safety of GSK Biologicals' HPV Vaccine in Healthy Women Aged 18-35 Years |
Completed |
NCT00345878
|
Phase 3 |
|
| 34 |
Evaluation of the Immune and Safety Response of GlaxoSmithKline (GSK) Biologicals' HPV Vaccine in Healthy Indian Women |
Completed |
NCT00344032
|
Phase 3 |
|
| 35 |
Immunogenicity of GlaxoSmithKline Biological's Human Papillomavirus (HPV) Vaccine (580299) Versus Merck's Gardasil® in Healthy Females 18-45 Years of Age |
Completed |
NCT00423046
|
Phase 3 |
|
| 36 |
Human Papillomavirus (HPV) Registration Study (Gardasil)(V501-023)(COMPLETED) |
Completed |
NCT00157950
|
Phase 3 |
|
| 37 |
Evaluation of Safety and Immunogenicity of Co-administering Human Papillomavirus Vaccine With Another Vaccine in Healthy Female Subjects |
Completed |
NCT00578227
|
Phase 3 |
|
| 38 |
A Study to Evaluate the Immune Response and Safety of GSK Biologicals' HPV-16/18 L1 VLP AS04 Vaccine/Cervarix TM Vaccine in Healthy Females Aged 15-25 Years |
Completed |
NCT00485732
|
Phase 3 |
|
| 39 |
A Study of Gardasil (V501) in Preadolescents and Adolescents (V501-018) |
Completed |
NCT00092547
|
Phase 3 |
|
| 40 |
Evaluation of Immunogenicity and Safety of Two 2-dose Human Papillomavirus (HPV) Vaccine Schedules in 9-14 Year Old Girls |
Completed |
NCT01381575
|
Phase 3 |
|
| 41 |
Immunogenicity and Safety of GlaxoSmithKline Biologicals' Huma Papillomavirus (HPV) Vaccine 580299 in Healthy Females 15 - 25 Years of Age |
Completed |
NCT00552279
|
Phase 3 |
|
| 42 |
ITIC (Imiquimod Therapy in Cervical Intraepithelial Neoplasia)-Trial |
Completed |
NCT00941252
|
Phase 2, Phase 3 |
Topical imiquimod therapy |
| 43 |
Randomized Clinical Trial on Clinical Management of ASCUS and LSIL (ALTS) |
Completed |
NCT01131312
|
Phase 3 |
|
| 44 |
A Study of the Safety, Tolerability, and Immunogenicity of a 9-valent Human Papillomavirus Vaccine ([9vHPV]; V503) Administered to 9- to 15-Year-Old Japanese Girls (V503-008). |
Completed |
NCT01254643
|
Phase 3 |
|
| 45 |
Effect of WHO-yaws Elimination Strategy in Lihir Island, Papua New Guinea |
Completed |
NCT01955252
|
Phase 3 |
Azithromycin |
| 46 |
Glizigen-Viudid-External Anogenital Warts in Children and Adolescents |
Completed |
NCT01111344
|
Phase 3 |
|
| 47 |
Immunogenicity and Safety of GSK Biologicals' HPV Vaccine 580299 in Healthy Japanese Females 10-15 Years of Age |
Completed |
NCT00492544
|
Phase 3 |
|
| 48 |
Complementary Testing to Evaluate Immunogenicity of Human Papillomavirus (HPV) Vaccine (580299) in Healthy Female Subjects Aged >/= 26 Years |
Completed |
NCT00456807
|
Phase 3 |
|
| 49 |
A Bridging Study of a Recombinant Human Papillomavirus 16/18 Bivalent Vaccine in Preadolescent Girls |
Completed |
NCT02562508
|
Phase 3 |
|
| 50 |
A Study of Amolimogene (ZYC101a) in Patients With High Grade Cervical Intraepithelial Lesions of the Uterine Cervix |
Completed |
NCT00264732
|
Phase 2, Phase 3 |
Amolimogene;Amolimogene |
Inferred drug relations via
UMLS
73
/
NDF-RT
51
:
|
